Apr 19, 20212 min read

Free Biopharma Daily Stock Updates - 04/19/21

$XBI $128.72 -2%

$TBIO +2% Published preclinical results of COVID-19 vaccine candidate, MRT5500 in npj Vaccines. source

$TNXP +10% Exclusive worldwide licensing agreement to develop SARS-CoV-2 inhibitor. source

$CYDY +7% Submitted manufacturing section of application for Leronlimab to treat COVID-19. source

$BNTX -2% and $PEE supply EU with 100 million additional doses of COMIRNATY. source

$ALLO -1% IND cleared by FDA for ALLO-605, CAR-T therapy, for multiple myeloma, ph 1 planned for mid 2021. source

$ANIX -14% FDA requests additional info for CAR-T therapy and study on clinical hold. source

$AGEN -2% Submitted BLA for balstilimab to treat cervical cancer. source

$OVID -5% Discontinued OV101 program to focus on OV882. source

$KRYS -3% Expanding rare genetic lung disease pipeline. source

$HGEN -7% Positive data reported for Lenzilumab in ZUMA-19 trial and will initiate registrational study. source

$AERI +1% Roclanda receives marketing authorization from MHRA in Great Britain. source

$UTHR +1% Tyvaso DPI submitted NDA. source

$CMPI -7% Initiated patient dosing in Phase 2 trial in combo with pembrolizumab. source

$XBIT -1% FDA granted permission to commence Phase 1/2 trial in pancreatic cancer. source

$ERYP +3% First cohort in Phase 1 Eryaspase trial completed. source

$PRTA -4% Phase 1 results of PRX004 presented at AAN 2021. source

$AMRN +1% Further analyses reported for VASCEPA to impact vulnerable coronary plaque features. source

$AVDL -2% Reports new data from REST-ON Phase 3 trial. source

$JAGX +1% Will host an interview Fri 4/23 at 8:30a est re: Napo EU, companies new Italian subsidiary. source

$NMTR -3% Collaboration with Duke Clinical Research Institute to support Short Bowel Syndrome Program. source

$AGTC -5% licenses technology to SpringVision SAS. source